

---

---

# FORM 6-K

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

For the month of July 2015

Commission File Number: 001-36686

### Forward Pharma A/S

Ostergade 24A, 1  
1100 Copenhagen K, Denmark

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).

Yes

No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).

Yes

No

---

---

### **Notice to Convene Extraordinary General Meeting**

On July 3, 2015, Forward Pharma A/S (the “Company”) mailed to its shareholders a notice to convene an extraordinary general meeting of shareholders on July 20, 2015 and accompanying documentation, as filed herewith.

### **Exhibits**

99.1	Notice to Convene Extraordinary General Meeting
99.2	Proxy/Voting Correspondence Form
99.3	Request for Admission Card
99.4	Share and Voting Rights

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

FORWARD PHARMA A/S

Date: July 6, 2015

By: /s/ Joel Sendek  
Joel Sendek  
Chief Financial Officer



Extraordinary General Meeting in Forward Pharma A/S

**NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING**

An extraordinary general meeting in Forward Pharma A/S will be held on

**Monday 20 July 2015 at 2.00 pm (CET)**

at the company's premises, Østergade 24A, 1st floor, 1100 Copenhagen K, Denmark.

**AGENDA**

- (a) Election of two new members to the board of directors.
- (b) Authorization of the chairman of the general meeting.

**ELABORATION ON THE ITEMS ON THE AGENDA**

**Item (a):**

The board of directors proposes that Grant Hellier Lawrence and Jakob Mosegaard Larsen are elected members of the board of directors.

Information about the competences and experience of the candidates is included in appendix 1.

**Item (b)**

The board of directors proposes that the chairman of the general meeting (or any representative appointed by him in his stead) is authorized to file the election of additional members of the board of directors to the Danish Business Authority and in this connection to make any such amendments and supplements to the application and the resolution that may be appropriate or required as a condition for registration.

---

## **ADDITIONAL INFORMATION**

### **Majority requirements**

All proposals on the agenda may be adopted by a simple majority of votes, cf. clause 8 of the articles of association.

### **Share capital**

The current registered share capital of the Company is DKK 4.665.589, divided into 46.655.890 shares of DKK 0.10 each. Each share of DKK 0.10 carries one vote.

In addition, the share capital was increased by nominally DKK 21,584.40, divided into 215,844 shares of DKK 0.10 each, by board resolution dated 23 June 2015 as a consequence of the exercise of warrants by two warrant holders. The capital increase has been filed with the Danish Business Authority but the registration has not been completed at the time of writing. The holders of the new shares are entitled to vote and exercise any other rights attached to the shares at the extraordinary general meeting.

### **Record date**

The record date is Thursday 13 July 2015 end of day (CET).

### **Participation and voting rights**

The right of a shareholder to attend and vote at a general meeting is determined by the shares held by the shareholder at the record date.

The shares held by each shareholder at the record date are calculated based on (i) the registration of the number of shares held by that shareholder in the company's register of shareholders and (ii) any notification of ownership received by the company for the purpose of registration in the company's register of shareholders, which has not yet been registered.

Participation is conditional on the shareholder having obtained an admission card in due time.

### **How to obtain an admission card**

Access to the extraordinary general meeting is conditional on the shareholder having requested an admission card by Thursday 16 July 2015 end of day (CET).

Admission cards for the extraordinary general meeting may be obtained by:

- contacting Forward Pharma A/S by phone +45 33 44 42 42, or
- returning the attached request for admission card form, duly completed and signed, by email: [art@forward-pharma.com](mailto:art@forward-pharma.com) or by ordinary letter to Forward Pharma A/S, Østergade 24A, 1, 1100 Copenhagen K, Denmark.

### **How to submit a proxy**

Proxies must reach Forward Pharma A/S by Friday 17 July 2015 end of day (CET).

Voting instructions by proxy may be completed and submitted by:

- returning the attached proxy form, duly completed and signed, by email: [art@forward-pharma.com](mailto:art@forward-pharma.com) or by ordinary letter to Forward Pharma A/S, Østergade 24A, 1, 1100 Copenhagen K, Denmark.

From shareholders unable to attend the extraordinary general meeting, the board of directors would appreciate receiving a proxy to exercise the voting rights attached to the shares to know the shareholders' view on the respective items on the agenda.

According to Danish law, a proxy issued to the board of directors for an extraordinary general meeting is only valid if it is in writing.

### **How to vote by correspondence**

Votes by correspondence must reach Forward Pharma A/S by Sunday 19 July 2015 end of day (CET).

Voting by correspondence may be completed and submitted by:

- returning the attached voting by correspondence form, duly completed and signed, by email: [art@forward-pharma.com](mailto:art@forward-pharma.com) or by ordinary letter to Forward Pharma A/S, Østergade 24A, 1, 1100 Copenhagen K, Denmark.

Votes by correspondence cannot be withdrawn.

**Information on the website**

Further information on the general meeting will be available on [www.forward-pharma.com](http://www.forward-pharma.com) → 'Investors' until and including the date of the extraordinary general meeting, including:

- The notice convening the general meeting;
- The total number of shares and voting rights on the date of the notice;
- The agenda and the complete proposals;
- The forms to be used for voting by proxy or voting by correspondence.

3 July 2015

The board of directors of Forward Pharma A/S

## **APPENDIX 1**

### **GRANT HELLIER LAWRENCE**

Grant Hellier Lawrence is currently Managing Director and CFO at Nunc A/S, a Thermo Fisher Scientific company. He has more than 15 years of financial and IT management experience within global Life Science manufacturing and commercial companies, where he has provided overall leadership and strategic direction with a proven record of driving sustained business and financial performance. Prior to joining Thermo Fisher Scientific, Mr Lawrence worked for FMC and Pioneer Electronic Corporation. Mr. Lawrence holds a Diploma in Mechanical Engineering (1984) and graduated from the University of South Africa with a Bachelor of Commerce Degree in Accounting and Business Administration (1989).

### **JAKOB MOSEGAARD LARSEN**

Jakob Mosegaard Larsen is a partner at Copenhagen based law firm, Nielsen Nørager LLP, and serves as a trusted advisor of Danish and international private equity and venture fund managers. He has several years of experience acting as a legal adviser of biotech and life science companies. He graduated from Copenhagen University with a Master Degree in Law and holds an executive MBA from Copenhagen Business School. Jakob Mosegaard Larsen is a member of the Danish Venture Capital and Private Equity Association's Legal Committee and serves as DVCA's representative on the European Private Equity & Venture Capital Association's (EVCA) Tax, Legal and Regulatory Committee. Jakob Mosegaard Larsen and Nielsen Nørager LLP act as Danish legal counsel to Forward Pharma A/S and the Nordic Biotech funds that currently are shareholders of Forward Pharma A/S. Jakob Mosegaard Larsen is also a member of the board of directors of the advisory company of two of the Nordic Biotech funds that currently are shareholders of Forward Pharma A/S.

---





Extraordinary General Meeting in Forward Pharma A/S

An extraordinary general meeting in Forward Pharma A/S will be held on Monday 20 July 2015 at 2:00 p.m. (CET) at the company’s premises, Østergade 24A, 1<sup>st</sup> floor, 1100 Copenhagen K, Denmark.

**PROXY/VOTING BY CORRESPONDENCE FORM**

Name: \_\_\_\_\_

Address: \_\_\_\_\_

(Please use CAPITAL LETTERS)

I/we hereby authorise by proxy/submit written votes (voting by correspondence) in accordance with the indications below:

Please check off field A), B), C) or D):

A)  Proxy is granted to a named third party (*deadline Friday 17 July 2015 (CET)*):

Name: \_\_\_\_\_

Address: \_\_\_\_\_

(Please use CAPITAL LETTERS)

*or*

B)  Proxy is granted to the board of directors (or order) to vote in accordance with the board of directors’ proposals as set out in the table below (*deadline Friday 17 July 2015 (CET)*).

*or*

C)  Check-the-box Proxy is granted to the board of directors (or order) to vote as stated below. Please check off the boxes “FOR”, “AGAINST” or “ABSTAIN” to indicate your vote (*deadline Friday 17 July 2015 (CET)*).

*or*

D)  Written votes (voting by correspondence) are submitted as stated below. Written votes cannot be withdrawn. Please check off the boxes “FOR”, “AGAINST” or “ABSTAIN” to indicate your vote (*deadline Sunday 19 July 2015 (CET)*).

**Agenda**

The full agenda is included in the notice to convene the extraordinary general meeting.

If the votes attached to a shareholder’s shares are cast differently in relation to a specific agenda item, this shall be indicated in the table below.

---

AGENDA ITEMS	FOR	AGAINST	ABSTAIN	RECOMMENDATION FROM THE BOARD
<b>(a) Election of two new members to the board of directors</b>				
<b>1) Jakob Mosegaard Larsen</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
<b>2) Grant Hellier Lawrence</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
<b>(b) Authorization of the chairman of the general meeting</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				

**If the form is only dated and signed, it will be regarded as a proxy to the board of directors to vote in accordance with the recommendations of the board of directors as stated above.**

**If the form is only partially completed, votes will be cast in accordance with the recommendations of the board of directors as stated above with respect to the non-ticked off boxes.**

The proxy applies to all business transacted at the extraordinary general meeting. In the event that new proposals are submitted, including amendments or proposals for election of members to the board of directors or auditor not on the agenda, the proxy holder will vote on your behalf according to his/her best belief. Written votes (voting by correspondence) will be taken into account if a new or an amended proposal is substantially the same as the original.

The proxy/voting by correspondence is valid for the number of shares that the undersigned is registered as owner of in the register of shareholders of the company as of Monday 13 July 2015 (CET) or the number of shares held which the undersigned has notified the company of on or before Monday 13 July 2015 (CET).

Date: 2015

Name:	Name:
Title:	Title:

*The dated and signed form, if used as a proxy (box A-C above), must reach Forward Pharma A/S by **Friday 17 July 2015 (CET)** either by email (art@forward-pharma.com) or by ordinary mail. If the form is used for written votes (voting by correspondence)(box D above), the form must reach Forward Pharma A/S no later than **Sunday 19 July 2015 (CET)** either by email (art@forward-pharma.com) or by ordinary mail.*



Extraordinary General Meeting in Forward Pharma A/S

An extraordinary general meeting in Forward Pharma A/S will be held on Monday 20 July 2015 at 2.00 p.m. (CET) at the company’s premises, Østergade 24A, 1<sup>st</sup> floor, 1100 Copenhagen K, Denmark.

**REQUEST FOR ADMISSION CARD**

Access to the extraordinary general meeting is conditional on the shareholder having requested an admission card by Thursday 16 July 2015 end of day (CET).

Admission cards for the extraordinary general meeting may be obtained by:

- contacting Forward Pharma A/S by phone +45 33 44 42 42, or
- returning this request for admission card form, duly completed and signed, by email: [art@forward-pharma.com](mailto:art@forward-pharma.com) or by ordinary letter to Forward Pharma A/S, Østergade 24A, 1, 1100 Copenhagen K, Denmark.

Please tick the relevant box(es):

- I/we will attend the extraordinary general meeting and hereby order an admission card
- I/we attend with advisor:

\_\_\_\_\_  
Name of advisor (please use CAPITAL LETTERS)

Further information on the general meeting is available on [www.forward-pharma.com](http://www.forward-pharma.com) → ‘Investors’, including the notice convening the general meeting and the agenda.

Date: 2015

On behalf of:

\_\_\_\_\_  
Name:  
Title:

\_\_\_\_\_  
Name:  
Title:

*If you wish to give proxy or vote by correspondence, please complete the proxy/voting by correspondence form. Please remember to sign and date the form.*





## SHARES AND VOTING RIGHTS AS PER 2 JULY 2015

SHARES	NOMINAL VALUE (DKK)	NO. OF SHARES (OF NOMINALLY DKK 0.10)	NO. OF VOTES
Registered shares	4,665,589	46,655,890	46,655,890
Shares subscribed for but not yet registered*(1)	21,584.40	215,844	215,844
Own holding of shares*(2)	0	0	0
<b>Registered shares and shares subscribed for but not yet registered, excluding own holding of shares</b>	<b>4,687,173.40</b>	<b>46,871,734</b>	<b>46,871,734</b>

\*(1) The share capital was increased by nominally DKK 21,584.40 by board resolution dated 23 June 2015 as a consequence of the exercise of warrants by two warrant holders. The capital increase has been filed with the Danish Business Authority but the registration has not been completed at the time of writing. The holders of the new shares are entitled to vote and exercise any other rights attached to the shares at the extraordinary general meeting.

\*(2) Voting rights cannot be exercised.